Jos Hendrik Beijnen

16PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical virologyPredictive and prognostic markersNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 08, 2026
Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A DPYD Variant Allele.

|Feb 16, 2026
Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma.

Mark C de Gooijer, Daria M Fedorushkova, Ping Zhang

|Nov 20, 2025
Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

Ma Ida Mohmaed Ali, Lisa T van der Heijden, Matthijs Tibben

|May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Alaa Embaby, Sanne C F A Huijberts, Liqin Wang

|Dec 01, 2023
Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.

David Damoiseaux, Alfred H Schinkel, Jos H Beijnen

|Nov 13, 2023
A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.

Jonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks

Pageof 3

Frequent Collaborators

5 joint publications

Alfred H Schinkel

3 joint publications

Jonathan E Knikman

3 joint publications

Henk-Jan Guchelaar

3 joint publications

Alwin D R Huitema